Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Juri | - |
dc.contributor.author | Park, Sung Woo | - |
dc.contributor.author | Yoon, Kun Ho | - |
dc.contributor.author | Kim, Sung Rae | - |
dc.contributor.author | Ahn, Kyu Jeung | - |
dc.contributor.author | Lee, Jae Hyuk | - |
dc.contributor.author | Mok, Ji Oh | - |
dc.contributor.author | Chung, Choon Hee | - |
dc.contributor.author | Han, Kyung Ah | - |
dc.contributor.author | Koh, Gwan Pyo | - |
dc.contributor.author | Kang, Jun Goo | - |
dc.contributor.author | Lee, Chang Beom | - |
dc.contributor.author | Kim, Seong Hwan | - |
dc.contributor.author | Kwon, Na Young | - |
dc.contributor.author | Kim, Doo Man | - |
dc.date.accessioned | 2021-07-30T05:17:18Z | - |
dc.date.available | 2021-07-30T05:17:18Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3976 | - |
dc.description.abstract | Aims: To evaluate the efficacy and safety of evogliptin, a newly developed dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes (T2D) inadequately controlled by diet and exercise. Materials and Methods: In this randomized, double-blind, placebo-controlled, parallel-group, multicentre, phase III study, 160 patients with T2D were assigned to either evogliptin 5 mg or placebo for 24 weeks. The primary endpoint was the mean change in glycated haemoglobin (HbA1c) from baseline to week 24. Results: The mean baseline HbA1c levels were similar in the evogliptin and the placebo groups (7.20% ± 0.56% vs 7.20% ± 0.63%, respectively). At week 24, evogliptin significantly reduced HbA1c levels from baseline compared with placebo (−0.23% vs 0.05%, respectively, P < .0001). Additionally, the proportion of patients achieving HbA1c <6.5% was significantly higher in the evogliptin group than in the placebo group (33.3% vs 15.2%; P = .008). The overall incidence of adverse events, including hypoglycaemia, was similar in the 2 groups. Conclusions: In this 24-week study, once-daily evogliptin monotherapy significantly improved glycaemic control and was well tolerated in patients with T2D. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Chang Beom | - |
dc.identifier.doi | 10.1111/dom.12987 | - |
dc.identifier.scopusid | 2-s2.0-85021855219 | - |
dc.identifier.wosid | 000414514600004 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.19, no.12, pp.1681 - 1687 | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 19 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1681 | - |
dc.citation.endPage | 1687 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject.keywordPlus | BETA-CELL FUNCTION | - |
dc.subject.keywordPlus | INADEQUATE GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | IV INHIBITOR | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | SITAGLIPTIN | - |
dc.subject.keywordPlus | VILDAGLIPTIN | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | INCRETIN | - |
dc.subject.keywordAuthor | antidiabetic drug | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | DPP-4 inhibitor | - |
dc.subject.keywordAuthor | phase III study | - |
dc.subject.keywordAuthor | type 2 diabetes | - |
dc.identifier.url | https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.12987 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.